Agenus Inc. got an unwelcome surprise from the US Food and Drug Administration, which recommended against the company filing for accelerated approval for the combination of its CTLA-4-targeting monoclonal antibody botensilimab and the PD-1-targeting balstilimab (BOT/BAL) in relapsed/refractory microsatellite-stable colorectal cancer (MSS CRC) with no active liver metastases.
Agenus Needs Phase III For BOT/BAL, Another Example Of Shifting Accelerated Approval Climate
The US FDA surprised some observers when it advised Agenus against filing for accelerated approval of the CTLA-4/PD-1 combination, but the agency has been cracking down on confirmatory trial requirements recently to better ensure the studies will be finished.
More from Review Pathways
• By
The Brazilian medicines regulator will also offer more clarity on the requirements for radiopharmaceuticals that are exempt from registration.
• By
Novartis is planning to file EU and US marketing applications for an intrathecal formulation of its spinal muscular atrophy gene therapy, Zolgensma, in H1 2025.
• By
The FDA’s accelerated approval draft guidance has left stakeholders seeking clarification of the process for determining a surrogate marker or intermediate clinical endpoint is reasonably likely to confirm clinical benefit.
• By
Experts working in the advanced therapy space say the US has less strict criteria for regulatory pathways for cell and gene therapies than the EU, particularly for products in early development.